Please assess the completion status of the following clinical trial:

Trial Title: Terlipressin Administration in Patients Undergoing Major Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing resection of 3 or more liver segments~* Minimum age of 18~* Any gender~* Written informed consent~Exclusion Criteria~* Preoperative renal failure (GFR \< 50ml/min)~* Severe liver dysfunction (Child-Turcotte-Pugh grade C)~* Hyponatremia (\<132mmol/l)~* Severe aortic regurgitation, severe mitral regurgitation, heart failure~* Symptomatic coronary heart disease~* Bradycardic arrhythmia (heart rate \< 60/min)~* Peripheral artery occlusive disease (clinical stadium II-IV)~* Dilatative arteriopathy, history of subarachnoidal bleeding~* Decompensated arterial hypertension (Blood pressure \>160/100mmHg despite intensive treatment)~* Present or suspected acute mesenteric ischemia~* Septic shock~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: ACTIVE_COMPARATOR): Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
- NaCl (Type: PLACEBO_COMPARATOR): Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).